The pilot study of MGC Pharma’s ArtemiC Support will put a measurement on the supplement’s effectiveness in treating the long-lasting impacts of COVID disease.

MGC Pharma (ASX:MXC), has kicked off a clinical study to determine the efficacy of its proprietary supplement ArtemiC Support in patients with Long COVID syndrome.

The collaboration with Swiss PharmaCan and Glow LifeTech will enroll 150 patients suffering from post-acute COVID syndrome, sometimes called Long COVID syndrome.

The syndrome refers to the long-lasting health issues affecting people post-COVID, ranging from respiratory illnesses through heart complications to chronic kidney impairment.

ArtemiC Support is the second product in the Company’s ArtemiC supplement product range to progress to the clinical trial phase.

In 2020, MGC Pharma undertook a Phase II clinical trial of its main supplement, ArtemiC, to determine its safety and efficacy in patients diagnosed with moderate COVID-19.

The ArtemiC supplement contains natural based ingredients consisting of artemisinin, curcumin, boswellia serrata, and Vitamin C.

“This study is a crucial first step in determining whether ArtemiC Support helps Long COVID sufferers by treating what are often very debilitating conditions,” says MGC Pharma CEO, Roby Zomer.

“We’re hopeful this study will demonstrate that ArtemiC Support is as successful at helping patients with Long COVID, as the Phase II study undertaken in 2020 indicated that ArtemiC was in treating patients with moderate COVID-19,” he continued.


ArtemiC Support could benefit millions

In this pilot study, patients will take ArtemiC Support for six weeks under medical supervision.

Progress will be measured against a Post-COVID Functional Scale (PCFS), and a 10-point Likert scale – one, two, three and six weeks after treatment commences.

Initially, the pilot study aims to obtain partial results on the effectiveness and safety of ArtemiC Support in improving the functional status and symptomatology of patients.

Further follow-up studies might then be conducted to get the full information on the efficacy and safety of the food supplement in patients suffering from Long-COVID, depending on the results of the initial pilot study.

The study will enroll 50 patients, and received an Ethics Committee approval from the Spanish Foundation, IDIAP Gordi Gol, earlier this month.

It will specifically measure how ArtemiC Support affects known COVID-19 symptoms such as dyspnea (shortness of breath), asthenia (abnormal physical weakness or lack of energy), anosmia (loss of senses of smell), ageusia (loss of sense of taste ), cough, headache, and mental confusion.

Dr. Dieter Russman, Swiss PharmaCan’s Responsible Person for this study, said that if successful, the study will benefit millions of people suffering from Long Covid.

“In October, Swiss PharmaCan gave the green light for a clinical study on the Influence of ArtemiC Support in patients with Long COVID,” he said.

“I’m expecting highly valuable results on the safety and efficacy of ArtemiC Support, based on its breakthrough MyCell technology, and the potential benefit for millions of people suffering from Long COVID who have had limited therapeutic options available to them.”

The MyCell technology is Swiss Pharma’s intellectual property asset, which is said to increase the bioavailability of the natural ingredients used in the formulation of ArtemiC.

The study is expected to conclude in February 2022, subject to enrolment targets being achieved, with results expected to be published in Q2 of 2022.

MGC Pharma reported in November that it has received around $1,000,000 ArtemiC order from Swiss Pharma, setting up the company for its best quarter and a half ever.

This article was developed in collaboration with MGC Pharma, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.